Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2016 Jan;10(1):1-98.
doi: 10.1007/s12072-015-9675-4. Epub 2015 Nov 13.

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

S K Sarin  1 , M Kumar  2 , G K Lau  3   4 , Z Abbas  5 , H L Y Chan  6 , C J Chen  7 , D S Chen  8 , H L Chen  9 , P J Chen  10 , R N Chien  11 , A K Dokmeci  12 , Ed Gane  13 , J L Hou  14 , W Jafri  15 , J Jia  16 , J H Kim  17 , C L Lai  18 , H C Lee  19 , S G Lim  20 , C J Liu  9 , S Locarnini  21 , M Al Mahtab  22 , R Mohamed  23 , M Omata  24 , J Park  25 , T Piratvisuth  26 , B C Sharma  27 , J Sollano  28 , F S Wang  29 , L Wei  30 , M F Yuen  31 , S S Zheng  32 , J H Kao  33
Affiliations
Practice Guideline

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

S K Sarin et al. Hepatol Int. 2016 Jan.

Abstract

Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection and the potential for therapy of the resultant disease is continuously improving. New data have become available since the previous APASL guidelines for management of HBV infection were published in 2012. The objective of this manuscript is to update the recommendations for the optimal management of chronic HBV infection. The 2015 guidelines were developed by a panel of Asian experts chosen by the APASL. The clinical practice guidelines are based on evidence from existing publications or, if evidence was unavailable, on the experts' personal experience and opinion after deliberations. Manuscripts and abstracts of important meetings published through January 2015 have been evaluated. This guideline covers the full spectrum of care of patients infected with hepatitis B, including new terminology, natural history, screening, vaccination, counseling, diagnosis, assessment of the stage of liver disease, the indications, timing, choice and duration of single or combination of antiviral drugs, screening for HCC, management in special situations like childhood, pregnancy, coinfections, renal impairment and pre- and post-liver transplant, and policy guidelines. However, areas of uncertainty still exist, and clinicians, patients, and public health authorities must therefore continue to make choices on the basis of the evolving evidence. The final clinical practice guidelines and recommendations are presented here, along with the relevant background information.

Keywords: Acute hepatitis; Guidelines; HBV.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Treatment indications for chronic HBV-infected patients with cirrhosis or reactivation of chronic HBV infection
Fig. 2
Fig. 2
Treatment indications for noncirrhotic HBeAg-positive chronic HBV-infected patients
Fig. 3
Fig. 3
Treatment indications for noncirrhotic HBeAg-negative chronic HBV-infected patients
Fig. 4
Fig. 4
Reverse transcriptase mutations associated with drug resistance
Fig. 5
Fig. 5
Cumulative incidence of antiviral resistance in long-term studies of NA therapy
Fig. 6
Fig. 6
Prophylaxis for prevention of HBV graft recurrence following LT
Fig. 7
Fig. 7
Treatment of CHB infection in HIV infected individuals
Fig. 8
Fig. 8
Treatment of HBV–HCV coinfected patients
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–926. doi: 10.1136/bmj.39489.470347.AD. - DOI - PMC - PubMed
    1. Schunemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336:1106–1110. doi: 10.1136/bmj.39500.677199.AE. - DOI - PMC - PubMed
    1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–2219. doi: 10.1016/j.vaccine.2011.12.116. - DOI - PubMed
    1. Liaw YF. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol. 2009;51:403–410. doi: 10.1016/j.jhep.2009.04.003. - DOI - PubMed
    1. Clements CJ, Baoping Y, Crouch A, et al. Progress in the control of hepatitis B infection in the western Pacific region. Vaccine. 2006;24:1975–1982. doi: 10.1016/j.vaccine.2005.11.035. - DOI - PubMed

Publication types

Substances